Versant Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Versant Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$39.6K	Buy	215 +5	+2%	+$1.09K	﹤0.01%	1566
2026 Q2	$51.4K	Hold	210	–	–	﹤0.01%	1334
2026 Q1	$35.5K	Buy	210 +6	+3%	+$1.04K	﹤0.01%	1449
2025 Q4	$37.3K	Hold	204	–	–	﹤0.01%	1245
2025 Q3	$24.8K	Buy	204 +203	+20,300%	+$22.9K	﹤0.01%	1467
2025 Q2	$104	Buy	+1	New	+$106	﹤0.01%	2614

Other funds holding AXSM

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

HB Wealth Management Atlanta, Georgia $19.5B AUM 16.96% 1-Year Est. Return

Iridian Asset Management Westport, Connecticut $275M AUM 37.66% 1-Year Est. Return

Baldwin Wealth Partners Marion, Massachusetts $1.52B AUM 21.45% 1-Year Est. Return

Washington Trust Advisors Wellesley, Massachusetts $1.4B AUM 26.88% 1-Year Est. Return

Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Stanley-Laman Group Berwyn, Pennsylvania $915M AUM 50.26% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Versant Capital Management's AXSM Position: Q3 2026 in Review

Versant Capital Management increased its Axsome Therapeutics (AXSM) stake by 2.4% in Q3 2026, buying an estimated $1.09K and bringing the position to 215 shares worth $39.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1566.

Versant Capital Management first reported a position in AXSM in Q2 2025 and has held it in 6 quarters since. The position peaked at $51.4K in Q2 2026. 111 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

Versant Capital Management held 215 shares of Axsome Therapeutics worth $39.6K as of Q3 2026.
Versant Capital Management bought 5 Axsome Therapeutics shares in Q3 2026, an estimated $1.09K.
Axsome Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #1566 holding.
Versant Capital Management first reported a position in Axsome Therapeutics in Q2 2025 and has held it in 6 quarters since.
Versant Capital Management's Axsome Therapeutics position peaked at $51.4K in Q2 2026.
111 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.